Sensyne Health PLC MagnifEye European regulatory certification (7426P)
21 Octubre 2021 - 1:00AM
UK Regulatory
TIDMSENS
RNS Number : 7426P
Sensyne Health PLC
21 October 2021
Test-To-Go System powered by MagnifEye receives European
regulatory certification
Oxford, U.K. and Dover, Delaware, USA, 21 October 2021: Sensyne
Health plc (LSE: SENS) ("Sensyne" or the "Company") the ethical
Clinical AI company, today announces that its licence and
development partner, Excalibur Healthcare Services Limited
("Excalibur"), has received European regulatory certification,
which includes the UK, for its 'Test-To-Go' COVID-19 antigen
testing system powered by Sensyne's MagnifEye Ô .
The Test-To-Go system powered by MagnifEye includes the
Excalibur lateral flow test ("LFT") CE-marked for self-testing, as
well as the CE marked 'Test to Go app', which includes Sensyne's
AI-powered image analysis technology MagnifEye Ô which provides
AI-enabled automated accurate and consistent reading of Excalibur
LFT results.
Excalibur together with Sensyne will work to drive adoption and
use throughout the European Economic Area and the United Kingdom in
the use of COVID-19 lateral flow testing across commercial and
government settings.
MagnifEye is already being used as part of the Department of
Health & Social Care's COVID-19 testing programme in the NHS
and has read and recorded more than one million lateral flow
antigen tests to date. Independent research has shown that the use
of MagnifEye significantly increases the reading accuracy of
lateral flow testing. [1]
About MagnifEye
MagnifEye is a deep learning algorithm capable of objectively
reading COVID-19 lateral flow tests with extremely high accuracy in
less than 2 seconds classifying tests as 'positive', 'negative',
'void' (where a test control line cannot be seen) or 'invalid'
(where the test fails to meet quality control criteria). MagnifEye
l everages a smartphone's camera capabilities, reading and
interpreting faint lines on lateral flow images to increase the
ability to identify positive tests, reduce fraudulent tests and
support infection control efforts. Importantly the technology is
also anticipated to identify COVID-19 cases with low viral load
which may have been missed by a human reader.
MagnifEye demonstrates how AI is now being used in healthcare
and represents one of the relatively few healthcare AI technologies
deployed for use in such a real world environment.
Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:
"This is a major scientific achievement and, we believe, a world
first in developing a regulated software application using state of
the art AI to enhance the accuracy of lateral flow testing and
reporting. This important milestone provides access to a key
commercial market and potentially will have a major positive impact
on improving the reporting of COVID lateral flow tests and
supporting societies' recovery from the pandemic.
"This news underlines the significant potential of our MagnifEye
technology which is helping to automate and improve the accuracy of
reading images in many diagnostic testing and medical imaging
applications."
Professor Sir Chris Evans, Chairman and Chief Executive of
Excalibur Healthcare Services , said: "This is a great result for
British technology and partnership between two UK-based companies.
I am delighted we secured this regulatory certification on behalf
of Excalibur and Sensyne and I am particularly excited about the
applications for non-Covid diagnostics we are developing in our
state-of-the-art laboratories in Cambridge."
-ENDS-
Sensyne Health
Lord (Paul) Drayson PhD FREng, Chief Executive
Officer +44 (0) 330 058
Dr Richard Pye, Chief Financial Officer 1845
Peel Hunt LLP (Nominated Adviser and Joint
Broker)
Dr Christopher Golden + 44 (0) 20 7418
James Steel 8900
Liberum (Joint Broker)
Bidhi Bhoma + 44 (0) 20 3100
Euan Brown 2000
Consilium Strategic Communications
Mary-Jane Elliott
Jessica Hodgson
CSCSensynehealth@consilium-comms.com +44 (0) 7780600290
SternIR
Julie Seidel
Julie.seidel@sternir.com +1 (212) 362-1200
About Sensyne Health www.sensynehealth.com
Sensyne Health plc Sensyne Health plc (LSE: SENS) is a clinical
artificial intelligence company operating a unique business model -
a for-profit plc making a positive social impact, sharing the
financial returns it makes with health systems. The company applies
clinical AI in the healthcare and life science industries. In
healthcare, Sensyne delivers r emote patient monitoring and
real-time decision-making systems for healthcare organizations and
their patients. In life sciences, Sensyne analyses large complex
anonymized data sets to help life sciences companies accelerate the
development of new medicines.
[1] Machine Learning for Determining Lateral Flow Device Results
in Asymptomatic Population: A Diagnostic
Accuracy Study, Andrew D Beggs et al, Available at SSRN: https://ssrn.com/abstract=3861638 or http://dx.doi.org/10.2139/ssrn.3861638
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCURAURAOURUUA
(END) Dow Jones Newswires
October 21, 2021 02:00 ET (06:00 GMT)
Sensyne Health (LSE:SENS)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Sensyne Health (LSE:SENS)
Gráfica de Acción Histórica
De May 2023 a May 2024
